Skip to main content
PLSE
NASDAQ Industrial Applications And Services

Chief Commercial Officer Resigns Immediately from Pulse Biosciences

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$18.73
Mkt Cap
$1.273B
52W Low
$12.56
52W High
$26.3
52W Position info
49% above low
Off High info
29% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

PLSE sits 49% above its 52-week low of $12.56.

Summary

Pulse Biosciences announced the immediate resignation of Kevin P. Danahy, its Chief Commercial Officer, a key executive in the company's early commercialization efforts.


Key Events · Executive and Board Changes · PLSE

  • Chief Commercial Officer Departs

    Kevin P. Danahy, the Chief Commercial Officer of Pulse Biosciences, Inc., resigned effective immediately on February 27, 2026.

  • Impact on Commercialization Efforts

    Mr. Danahy was noted as important to the company's early commercialization efforts, and his immediate departure creates a leadership gap as the company aims to leverage recent positive clinical data and regulatory approvals.

  • No Disagreement Stated

    The company explicitly stated that the resignation was not a result of any disagreement regarding operations, policies, practices, or accounting issues.


Analysis · PLSE · Industrial Applications And Services

The immediate resignation of Kevin P. Danahy, Chief Commercial Officer, is a notable development for Pulse Biosciences. While the company stated the departure was not due to disagreements, the loss of a CCO, particularly one described as "an important part of senior management as well as the Company's early commercialization efforts," creates a leadership void in a critical area. This comes shortly after the company announced compelling clinical data and FDA approval for its nPulse Cardiac Catheter on February 19, 2026, making the timing of a key commercial leader's exit particularly impactful as the company looks to capitalize on these advancements. Investors will likely monitor for details on a successor and any potential shifts in commercial strategy.

How filings like this one have moved

In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PLSE was trading at $18.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $12.56 to $26.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PLSE - Latest Insights

PLSE
Aug 06, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $53.33 info
Change: +$14.93 (+39%) info
Market Cap: $3.778B info
PLSE
Aug 06, 2026, 5:04 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $38.40
Real-time Price: $53.33 info
Change: +$14.93 (+39%) info
Market Cap: $3.778B info
PLSE
Aug 06, 2026, 4:21 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $36.23
Real-time Price: $53.33 info
Change: +$17.10 (+47%) info
Market Cap: $3.778B info
PLSE
Aug 06, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.23
Real-time Price: $53.33 info
Change: +$17.10 (+47%) info
Market Cap: $3.778B info
PLSE
Jul 29, 2026, 9:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.35
Real-time Price: $53.33 info
Change: +$17.98 (+51%) info
Market Cap: $3.778B info